Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys ...

Shares of Sarepta Therapeutics SRPT nosedived 42% in pre-market today after the company reported a second patient death following treatment with Elevidys, its one-shot gene therapy for Duchenne ...

The first death — a teenage boy who also died from acute liver failure after receiving Elevidys — was reported by the company in March. Both deaths occurred in non-ambulatory individuals with DMD.

Sarepta Therapeutics said a second patient had died after receiving its $3.2 million gene therapy to treat Duchenne muscular dystrophy.

Second patient death reported with gene therapy for muscular dystrophy The U.S. Food and Drug Administration campus in Silver Spring, Md., is photographed, Oct. 14, 2015. Credit: AP/Andrew Harnik ...

According to Sarepta, the patient was the second to succumb to acute liver failure (ALF) after being treated with Elevidys, which is the only gene therapy that has won FDA approval as a treatment ...

Sarepta disclosed the first patient death — a 16-year-old boy — in March. Both occurred from acute liver failure, a side effect that has been seen with other gene therapies.

Shares of Sarepta Therapeutics SRPT nosedived 42% in pre-market today after the company reported a second patient death following treatment with Elevidys, its one-shot gene therapy for Duchenne ...

WASHINGTON (AP) — Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

The second death, like an earlier one reported in March, occurred in a teenage boy who suffered a fatal case of acute liver injury, a known side effect of the therapy. Older patients receive a ...